17th Annual Heart Failure 2013: Update on Diagnosis and Therapy

Heart Failure 2013 has been designed to continue a tradition of providing a comprehensive, high level and clinically oriented update on prevention, diagnosis and management of heart failure. The program is structured to include lectures presented by experts in the field combined with interactive panel discussions. This year we made an attempt to cover an extensive list of topics including use of sympathetic denervation for treatment of resistant hypertension, diagnosis and treatment of sleep apnea, new treatments for hyponatremia, introduction of relaxin, a new drug in the management of acute decompensated heart failure, diuretics and ultrafiltration for the management of volume overload, new concepts in the diagnosis and management of diastolic heart failure, nitric oxide enhancing therapy for chronic heart failure, new drugs for stroke prevention as well as catheter ablation in patients with atrial fibrillation, new guidelines for the use of CRT and ICD in patients with heart failure and hypertrophic cardiomyopathy, use of MRI in the diagnosis and prognosis of cardiomyopathies, determination of myocardial viability in patients with coronary artery disease and LV dysfunction and methods for effective prevention of rehospitalizations. In addition the program will provide an update on cutting edge therapies including the use of gene therapy, neuroregulin and stem cell therapy in patients with heart failure. As in past years the program was designed to provide a high level and clinically oriented update with the goal of improving the care of patients with heart failure. I hope that you will join us for an exiting symposium.